Navigation Links
VENENUM Biodesign to Exhibit at SBS
Date:3/22/2011

HAMILTON, N.J., March 22, 2011 /PRNewswire/ -- VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today that it will be exhibiting at the 17th SBS Annual Conference & Exhibition at the Gaylord Palms Resort and Convention Center in Orlando, Florida, March 27-31, 2011. VENENUM Biodesign will be exhibiting at booth #524.

VENENUM Biodesign was established with the mission to improve patients' lives through the discovery of new therapeutic compounds. They are committed to building platforms for drug discovery research from novel targets to preclinical implementation. VENENUM Biodesign, a company within the Genesis Biotechnology Group, is located in "Einstein's Alley," the research and technology corridor in Hamilton, New Jersey. Their facility is easily accessible to other academic medical centers, biotech, and pharmaceutical companies in the New York, New Jersey, and Pennsylvania area.

This new facility is a unique blend of upscale office space with state-of-the-art laboratory facilities designed with a specialized floor plan to accommodate the Biodesign Compound Collection, which includes 5.5 million proprietary compounds (the "ECLiPS" collection), six newly designed VENENUM Targeted Libraries (VTLs), and approximately 80,000 compounds from commercial sources. This small molecule collection is one of the largest in the world and, combined with state-of-the-art UHTS capabilities, is a powerful tool to generate quality platforms for drug discovery.

There are expansive laboratories to accommodate mammalian and yeast cell culture, siRNA technology, protein engineering and production, cellular reagent generation, structural biology, and in vitro assay and in vivo model development. VENENUM Biodesign's new facility has been engineered to specifically accommodate their well-published and experienced Target Biology department, which identifies and validates novel targets. They are currently completing additional laboratory space immediately adjacent to the Target Biology Division to accommodate a growing Medicinal Chemistry team which implements and executes Hit-to-Lead and Lead Optimization programs.

According to Dr. Maria Webb, Chief Scientific Officer (CSO), "VENENUM is well-positioned with full ranging 'Gene to Lead' capabilities in early drug discovery to partner with pharma and non-profits. We are actively seeking those collaborations. VENENUM is also working to identify hits against novel targets and advance these through our Medicinal Chemistry."

To find out more, please visit http://www.venenumbiodesign.com.

Contact:

Maria Webb, Ph.D.
Chief Scientific Officer (CSO)
mwebb@venenumbiodesign.com
877.950.1032
http://www.venenumbiodesign.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE VENENUM Biodesign
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments
2. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposiumâ„¢
3. Nanowires exhibit giant piezoelectricity
4. At RSNA, DR Systems Will Exhibit New Unity v-Series Web PACS
5. WAVE Conference and Exhibition 2011 Taking Products to Market incorporating Micro & Nano Technology
6. Graphene exhibits bizarre new behavior well suited to electronic devices
7. Corgenix to Exhibit AspirinWorks(R) Test at Pri-Med New York
8. PRA International Exhibits at European Hematology Association Congress
9. DATATRAK Exhibiting at the DIAs 46th Annual Meeting
10. Sinovac to Participate at 2010 Shanghai CPhI Exhibition
11. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 63rd PHARMACHINA Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... OH (PRWEB) , ... August 16, 2017 , ... ... a beneficial microbe delivery system, announced it has secured $2M in funding from ... Queen City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar ...
(Date:8/16/2017)... and OXFORD, England , Aug. 16, 2017 ... for biotech executive search and leadership development, and Virdis Group, ... have created an exclusive alliance that enables clients to leverage ... "For our clients here in the ... access to a diverse population of leadership talent throughout the ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics , ... development, announces the launch of the new NHS Agile biosensor chip . ... data for a wide range of molecules, including small and large molecules, peptides, ...
(Date:8/15/2017)... ... 2017 , ... Kenall, a leader in sealed solid-state lighting, ... sealed and perform efficiently for years. The downlights are ideal for a variety ... such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and pharmaceutical processing ...
Breaking Biology Technology:
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Vehicle Anti-Theft ... 8.8% over the next decade to reach approximately $14.21 billion by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):